Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Ipsen    IPN   FR0010259150

IPSEN (IPN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Ipsen : supports awareness of Neuroendocrine Tumors (NET) and the NET Cancer Day on November 10, 2017

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 04:24pm CET

NET Cancer Day on the 10th of November 2017, is an annual event dedicated to raising awareness of a rare cancer, neuroendocrine tumors (NET).


NET Cancer Day, a global initiative of the International Neuroendocrine Cancer Alliance (INCA) and its members, aims to inform and raise awareness of this often undetected and rare disease amongst the general public and medical institutions with the ultimate goal of providing patients with improved diagnosis and care as they live with NET.
Neuroendocrine tumors: An unusual type of cancer

For more information on NET disease and Cancer Day please visit:
International Neuroendocrine Cancer Alliance
Living with NETs

Livingwithnets.com Website and its contents are intended for an international audience, excluding the United States, Canada and France.

Ipsen SA published this content on 10 November 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 10 November 2017 15:23:04 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IPSEN
02/17IPSEN : Rare medullary thyroid cancer treatment gets nod from NICE
AQ
02/15European shares build on recovery, Airbus shines
RE
02/15EXELIXIS : Announces Results from a Phase 2 Investigator-Sponsored Trial of Cabo..
AQ
02/15MS TRIAL ALERT : Investigators Recruiting for Phase III Trial of Dysport (abobot..
AQ
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15IPSEN : International Childhood Cancer Day, Ipsen mobilizes its teams
PU
02/15IPSEN : delivers strong 2017 results with 21.1% sales growth and..
PU
02/14IPSEN : Full Year 2017 Financial Results
PU
02/07IPSEN : announces eight oral presentations from its Neurosciences portfolio at t..
AQ
01/31IPSEN : Dr Sotirios G. Stergiopoulos appointed as Ipsen Chief Medical Officer
AQ
More news
News from SeekingAlpha
02/15Ipsen's (IPSEY) CEO David Meek on Q4 2017 Results - Earnings Call Transcript 
02/15Ipsen S.A. ADR 2017 Q4 - Results - Earnings Call Slides 
02/15Ipsen S.A. ADR reports FY results 
01/22Ipsen (IPSEF) Presents On Celestial, Phase 3 Trial Of Cabozantinib In HCC - S.. 
01/193 THINGS IN BIOTECH YOU SHOULD LEARN : January 18, 2018 
Financials (€)
Sales 2018 2 221 M
EBIT 2018 587 M
Net income 2018 394 M
Debt 2018 174 M
Yield 2018 0,95%
P/E ratio 2018 25,65
P/E ratio 2019 20,94
EV / Sales 2018 4,60x
EV / Sales 2019 4,04x
Capitalization 10 048 M
Chart IPSEN
Duration : Period :
Ipsen Technical Analysis Chart | IPN | FR0010259150 | 4-Traders
Technical analysis trends IPSEN
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 129 €
Spread / Average Target 7,7%
EPS Revisions
Managers
NameTitle
David D. Meek Chief Executive Officer
Marc M. P. de Garidel Non-Executive Chairman
Aymeric Le Chatelier Executive Vice President-Finance
Jonathan Barnsley Executive Vice President-Technical Operations
Alexandre P. LeBeaut Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
IPSEN15.55%12 081
JOHNSON & JOHNSON-7.19%352 552
NOVARTIS-3.37%224 301
PFIZER-2.84%212 857
ROCHE HOLDING LTD.-9.37%210 327
MERCK AND COMPANY-0.50%149 572